Intra-Cellular Ther ITCI

$URGN This is not investment advice because we have no idea what will happen to UroGen. We'd only remind investors $ITCI announced they settled a similar patent dispute allowing Sandoz to market a generic Caplyta by 2040. ITCI announced the settlement 2 or 3 days before they announced they were being acquired by $JNJ Again, this is not investment advice. $TEVA can market a generic Jelmyto in 2030 which (most likely) limits Jelmyto's M&A valuation. Of course Zusduri is anticipated to outsell Jelmyto 7 or so to 1. Good luck

$ATAI 3. BOARDROOM SHUFFLE & "THE BRAUNSTEIN FACTOR" ​Scott Braunstein: Appointed Vice Chairman. He is a heavyweight (CEO of $ITCI) who knows how to scale CNS blockbusters. ​Cosmo’s Strategic Exit: Cosmo Feilding-Mellen resigned from the BOD (Jan 6) but retained his massive share count. This removes potential "conflict of interest" hurdles during a buyout while keeping the founder's upside locked in.

$NMRA longer term view remains largely unchanged, Neumora’s price action closely mirrors Wave Life Sciences $WVE that plummeted ~50% on March 26 after disappointing obesity data. This suggests the market recently stripped the Obesity Premium out of mid-cap biotechs, hitting $NMRA particularly hard because of its own 1-year delay for NMRA-215. Pure-play psychiatry stocks like Axsome ($AXSM) and Intra-Cellular ($ITCI) have remained remarkably stable. This is evidence that $NMRA’s drop is not a rejection of its depression drug (Navacaprant), but rather a specific reaction to the obesity setback. Historically when a stock drops 30%+ on a secondary asset delay (Obesity) while the primary asset (Depression) stays on track, it leads to a reversion once the panic selling subsides. Long term view much higher with buyout potential probably pushed to 2027 https://www.marketbeat.com/instant-alerts/neumora-therapeutics-sees-unusually-large-options-volume-nasdaqnmra-2026-03-30/#google_vignette

$VNDA 🚨 Just got FDA APPROVAL for tradipitant (motion sickness) ✅ That’s real, commercial revenue starting now. And it’s not done… 👉 Another FDA decision as early as FEBRUARY 👉 Additional indications still in the pipeline Each approval = new revenue on top of existing sales!!! Market still pricing this like a one-and-done story. IMO there’s more upside ahead 🚀 $AXSM $ITCI $NBIX 💊📈

RBC Capital updates rating for Intra-Cellular Therapies ( $ITCI ) to Outperform, target set at 112 → 108.

RBC Capital updates rating for Intra-Cellular Therapies ( $ITCI ) to Outperform, target set at 76.

$LQDA feels like $ITCI in that the last remaining hurdle =IP overhang Intra-Cellular settled with Sandoz (Caplyta protection until 2040) on Jan 10, 3 days later $JNJ bought out for $14.6B Usual caveats (waiting on judge decision), but feels like we've seen this movie before...

$BCRX First of the scam dominos has fallen in $AVXL Next to go it $BCRX and then Inshallah one of the more disgusting scams that has ever actually succeeded in the American markets $ITCI whose drug at the market really does nothing except makes patients too tired to accurately score their self-determined evaluation scores against their baseline scores which were all taken while they are in acute withdrawl from other mood altering anti-psychotics.